| 本文已被：浏览 623次 下载 181次 |
码上扫一扫！ |
| 贝林妥欧单抗应用于儿童急性淋巴细胞白血病临床评价 |
| 张磊,陈潇,官慧,徐以凤,魏平平,李丹妮,丁雯雯,庄超,梁卉 |
|
|
| ((青岛大学附属妇女儿童医院,山东青岛 266034)) |
|
| 摘要: |
| 目的:探讨贝林妥欧单抗应用于儿童急性淋巴细胞白血病(ALL)的安全性及有效性,并分析院外治疗新模式,为ALL 的
诊疗提供参考。方法:回顾性分析2022 年8 月至2024 年8 月青岛大学附属妇女儿童医院应用贝林妥欧单抗治疗24 例ALL 患
儿的临床资料,评估治疗前后的基线资料及症状缓解情况。其中3 例患儿使用便携泵进行院外输注治疗模式。结果:7 例初始
治疗时微小残留病灶(MRD)持续阳性患儿,MRD 缓解率达100%;E2A:PBX1 融合基因阳性患儿转阴;BCR-ABLP190 融合基因
阳性患儿的基因定量降至0. 02%,后续桥接移植顺利。5 例复发患儿,经治疗后缓解率达100%;10 例合并严重并发症患儿,经
贝林妥欧单抗桥接治疗,MRD 保持持续缓解状态;3 例患儿采用院外输注治疗模式,过程顺利;所有患儿治疗过程中均无严重不
良反应发生。结论:贝林妥欧单抗应用于ALL 患儿的短期疗效显著,安全性、可控性高。本研究对院外治疗模式进行初探,今
后仍需长期随访及大样本数据进一步总结。 |
| 关键词: 贝林妥欧单抗 急性淋巴细胞白血病 儿童 院外输注 临床疗效 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2025.07.010 |
|
| 基金项目: |
|
| Clinical Efficacy Evaluation of Brentuximab in the Treatment of Children with Acute LymphoblasticLeukemia |
| Zhang Lei, Chen Xiao, Guan Hui, Xu Yifeng, Wei Pingping, Li Danni, Ding Wenwen, Zhuang Chao, Liang Hui |
| ((Women and Children’s Hospital, Qingdao University, Shandong Qingdao 266034, China)) |
| Abstract: |
| Objective: To probe into the safety and efficacy of brentuximab in the treatment of children with acute lymphoblastic
leukemia (ALL), and analyze new model of out-of-hospital treatment, so as to provide reference for the diagnosis and treatment of ALL.
Methods: Retrospective analysis was performed on clinical data of 24 children with ALL treated with bevacizumab at Women and
Children’s Hospital, Qingdao University from Aug. 2022 to Aug. 2024. Baseline data and remission status before and after treatment
were evaluated. Three cases received out-of-hospital infusion therapy by using portable pumps. Results: Seven newly diagnosed
patients, with persistent minimal residual disease (MRD), showed a MRD remission rate of 100%. One child with a positive E2A:PBX1
fusion gene achieved conversion to negative status. Patients with the BCR-ABLP190 fusion gene showed a reduction in gene
quantification to 0. 02%, followed by successful bridging transplantation. Five relapsed cases achieved a 100% remission rate after
treatment. Ten cases with severe complications underwent bridging therapy with brentuximab, achieved sustained MRD remission. The
out-of-hospital infusion therapy for the 3 cases proceeded smoothly, and no severe adverse drug reactions occurred during the treatment.
Conclusion: Brentuximab demonstrates significant short-term efficacy in children with ALL, with higher safety and controllability. This
study is a preliminary exploration of out-of-hospital treatment model, and it still needs long-term follow-up and large sample data for
further summary. |
| Key words: brentuximab acute lymphoblastic leukemia children out-of-hospital infusion clinical efficacy |
